Neuphoria Therapeutics Inc.
Income Statement
| Line Item | FY2025 |
|---|---|
| Revenue | $15.6M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $9.0M |
| SG&A Expense | $7.8M |
| Operating Income | $-1.1M |
| Operating Margin | -7.2% |
| Interest Expense | — |
| Pretax Income | $-838.0K |
| Income Tax Expense | $-468.4K |
| Net Income | $-369.6K |
| Net Margin | -2.4% |
| EPS (Basic) | $-0.23 |
| EPS (Diluted) | $-0.23 |
| Shares Outstanding (Basic) | 1.6M |
| Shares Outstanding (Diluted) | 1.6M |
| Dividends Per Share | — |